- 14th - 15th May 2026
- London, United Kingdom
Precision Medicine Global Congress 2026 Europe
Advancing Precision Medicine Through Innovation, Collaboration, and Sustainable Access
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
precision for medicine
Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to a subgroup of patients, instead of a one‐drug‐fits‐all model
Dear Colleagues,
FACILITATE LIVE is delighted to invite you to our Precision Medicine Global Congress 2026 Europe: Advancing Precision Medicine Through Innovation, Collaboration, and Sustainable Access.
Personalised medicine has moved beyond scientific promise into a defining era of clinical transformation. Breakthroughs in gene editing, RNA therapeutics, next-generation immunotherapies, multi omics integration, and AI driven analytics are reshaping how diseases are diagnosed, treated, and even prevented. What was once considered experimental is now entering mainstream clinical pathways. As these innovations move rapidly toward clinical adoption, healthcare systems worldwide face a critical challenge: ensuring that scientific progress is matched by regulatory readiness, sustainable financing, scalable manufacturing, and equitable access.
This two-day program brings together leaders from pharma, biotech, healthcare systems, government agencies, regulatory authorities, technology providers, and patient advocacy organizations to address the critical challenges directly. The agenda is structured to reflect the full lifecycle of personalised medicine — from scientific advancement and digital convergence to implementation, sustainability, and equitable access.
The foundational pillars of precision medicine currently focus on scaling clinical genomics, validating AI- enabled biomarkers, integrating multi-omics into clinical workflows, redesigning biomarker driven trials, and building secure, interoperable data ecosystems. Current discussions emphasize that discovery is no longer the primary limiting factor; instead, clinical utility, regulatory clarity, data governance, and system integration are the key determinants of whether innovation translates into measurable patient impact.
Furthermore, the advanced therapy era characterized by gene editing, RNA platforms, and cell-based immunotherapies is redefining medical possibilities with the potential for curative outcomes. These modalities challenge conventional healthcare economics and infrastructure. Our program addresses these critical issues, including outcome based reimbursement for one-time therapies, scaling GMP manufacturing, companion diagnostic alignment, workforce readiness, long-term patient monitoring, and global equity in access.
Across both days, several unifying themes emerge. First, the future of precision medicine is platform-based and data-driven, requiring robust governance frameworks to ensure transparency, trust, and safety. Second, sustainability – financial, operational, and regulatory will determine whether advanced therapies reach all eligible patients or remain limited to select populations. Third, collaboration across sectors is no longer optional. The complexity of programmable medicine demands coordinated leadership from industry, policymakers, healthcare providers, and patient communities.
Ultimately, this gathering is not only about scientific progress. It is about responsibility. As personalised medicine transitions from innovation to implementation, the success of this field will be judged not only by therapeutic breakthroughs, but by collective ability to scale them ethically, affordably, and equitably.
The defining challenge ahead is clear: we have the science — now we must build the systems to support it.
We look forward to welcoming you to the congress!
Sincerely yours,
Jocelyn Raguindin,
Conference Director,
FACILITATE LIVE
Gain Latest Insights on:
- While scientific breakthroughs in gene editing, RNA, and AI are accelerating, the primary bottlenecks have shifted to infrastructure, financing, regulation, and system integration.
- Technologies such as RNA and AI are now programmable platforms rather than single products, requiring adapted regulatory and development strategies.
- Beyond biomarker discovery, success requires validated clinical utility, reproducibility, and clear pathways to reimbursement.
- Integrating multi modal AI requires proactive addressing of transparency, bias mitigation, liability, and regulatory classification.
- One-time curative therapies challenge traditional healthcare budgeting, insurance risk pools, and payer sustainability.
- Global access is increasingly defined by the ability to scale GMP production and secure supply chains.
- To avoid delays and inequities, drug diagnostic co development must be synchronized.
- Long-term outcome tracking is now a structural requirement for regulatory approval and reimbursement.
- Shifting from reactive to predictive care through digital twins and genomics requires entirely new operational models.
- To avoid embedding bias, diversity must be actively corrected in genomic datasets and clinical trial populations.
- Standardizing global approval processes is critical to reducing development costs and accelerating access.
- Sustainable implementation is currently threatened by shortages in specialized technical and clinical personnel.
- Interoperability, privacy frameworks, and federated learning are foundational requirements for precision medicine.
- Transparent governance and patient engagement are essential to maintaining confidence in genomic surveillance and AI- driven decisions.
- Sustainable progress requires coordinated action among industry, regulators, payers, and patient groups.
Who should attend:
This forum is designed for senior leaders and decision makers across the personalised medicine ecosystem, including:
Pharmaceutical & Biotechnology Executives
- CEOs, CSOs, CMOs, Heads of R&D
- Precision Medicine Leaders
- Gene & Cell Therapy Directors
- Regulatory Affairs, Market Access
- Advanced Therapy Manufacturing Executives
Healthcare System & Clinical Leaders
- Chief Medical and Digital Officers
- Genomic Medicine Directors
- Oncology & Rare Disease Program Leads
- Clinical Trial Directors
- Molecular Pathology Heads
Government & Regulatory Authorities
- Regulatory Agency Representatives
- HTA Leaders
- National Genomics Program Directors
- Public Health Policymakers
- Health Innovation Advisors
Payers & Health Economics Experts
- Reimbursement Authorities, HEOR Leaders
- Insurance Executives
- Value-Based Contracting Specialists
- Budget Impact Strategists
Technology & Data Infrastructure Leaders
- Chief Technology Officers
- AI & Health Data Platform Executives Interoperability Strategists
- Cybersecurity Leaders
- Digital Health Innovators
Diagnostics & Manufacturing Specialists
- Companion Diagnostics Executives
- Laboratory Network Directors
- CDMO Leaders
- GMP Operations Heads
- Bioprocess Engineering Experts
Patient Advocacy & Non-Profit Leaders
- Patient Organization Executives
- Health Equity Advocates
- Access Policy Leaders
Academic & Research Institutions
- Translational Scientists, Genomics Researchers
- Clinical Investigators
- Bioinformatics Leaders
- Health Policy Experts
speakers
0
days
0
Presentations
0
Attendees
0
Key Industry Expert Speakers
Meet Our Professionals
Christine Von Raesfeld
Founder & CEO, People with Empathy, USA
MARTIN BRUNNINGER
Director General, Department of Health & Social Care for Austria
Schedule
Our Conference Production Team are now at the final stages of the overall complete program agenda - which will be available below shortly.
Translating scientific breakthroughs into scalable clinical systems
09:00 - OPENING KEYNOTE PANEL: Scaling Personalised Medicine: From Innovation to System-Level Impact
- Moving beyond pilot programs to national-scale implementation
- Aligning regulatory pathways with innovation speed
- Evidence generation: what payers and governments require
- Co-development models (drug + diagnostic + digital companion)
- Embedding patient voice early in therapeutic design
- Analyzing current adoption rates and regional developments across international markets.
- Examining the evolving frameworks designed to bring personalized therapies to market more efficiently.
- Identifying the systemic and technological hurdles that currently limit widespread scalability.
- Developing actionable strategies to integrate these advancements into standard healthcare delivery.
- Explore the integration of genomics, transcriptomics, proteomics, and metabolomics
- Focus on the role of systems biology in disease stratification
- Address the clinical validation of multi-omic signatures
- The ongoing challenges regarding data interoperability
- Strategies for translating these complex datasets into physician-ready insights that can be applied in a
clinical setting.
- Transitioning from research sequencing to clinical-grade pipelines
- Harmonizing variant interpretation across institutions
- Integrating genomic data into hospital EHR systems
- Accreditation, quality assurance, and compliance frameworks
- Workforce and bioinformatics capacity building
- Embedding PGx into electronic health record-based prescribing systems to provide real-time decision support.
- Utilizing genotype-guided therapy to significantly reduce adverse drug reactions.
- Establishing robust cost-effectiveness evidence to secure support from payers.
- Developing national implementation frameworks to standardize practices.
- Identifying and overcoming barriers to clinician adoption through education and streamlined workflows.
- Strategies for aligning drug and diagnostic timelines.
- Navigating cross-agency requirements and ensuring compliance.
- Standards for establishing clinical validity and utility.
- Synchronizing strategies between pharmaceutical and diagnostic partners to ensure market access and sustainable reimbursement.
The Data-Driven Infrastructure of Precision Medicine
- Examining computational models for treatment optimization
- Use of predictive modeling for disease progression.
- The integration of wearable and remote monitoring data to enhance model accuracy.
- Ethical implications of predictive health forecasting
- Practical challenges of clinical adoption and reimbursement.
- Multi-modal AI models integrating imaging, omics, and EHR data
- Validation frameworks for AI-derived biomarkers
- Bias detection and mitigation in training datasets
- Regulatory approval pathways for AI-driven diagnostics
- Real-world performance monitoring
- Leveraging longitudinal EHR and claims data
- Synthetic control arms in rare disease trials
- Data standardization and quality frameworks
- Global regulatory acceptance trends
- RWE in post-market surveillance
- Focus on establishing cross-border genomic data sharing frameworks
- Implementation of federated AI models that function without the need for centralizing sensitive data.
- Addressing critical cyber security threats facing genomic infrastructure and the modernization of patient consent processes.
- Effective strategies that balances technological innovation with the maintenance of public trust.
- Implementation of basket, umbrella, and platform trial designs
- Biomarker-driven patient stratification to ensure more targeted treatment.
- Transition toward decentralized and hybrid trial models to increase patient accessibility
- AI-assisted patient recruitment and advocating for the global harmonization of trial regulations.
- Who owns genomic and real-world data?
- Public-private data partnerships: risks and opportunities
- Balancing innovation with privacy protection
- Data standardization and interoperability challenges
- Building patient trust in AI-driven healthcare
COLLECTIVE DATA AND DIGITAL AGE
- How the focus on digital patient engagement helps healthcare providers create a greatly improved personalized patient experience from start to finish.
- Imperative for engaging end-users in each phase of digital health design
- Techniques to facilitate better digital health design and implementation.
- Bridging the divide between technology companies, patients, and clinicians regarding effective development and use of digital health
- The need to develop new, scalable and expandable big data infrastructure and analytical methods
- The nature of big data and the role of semantic web and data analysis for generating “smart data”
- How to create a system that makes big data robust and smart for healthcare providers and patients
- Accessing unlimited online opportunity to learn more about diseases, seek and or give assistance.
- Importance of finding and connecting with others infected or affected by the same illness or disease.
- Opportunity to exchange relevant data on their condition, treatment , symptoms, side effects, etc.
- Addressing the challenge of data protection to ‘go digital’
- The fundamental rights to privacy and to the protection of personal data have become more important for the protection of human dignity than ever before.
- Ethical dimension of data processing.
- The need for a new regulatory framework, guaranteeing the rights of individuals.
- Drivers and scale-up capabilities to advance RWD life cycle
- Adopting the best practices and overcoming the associated challenges
- Gauging the progress brought to downstream use by better data life cycle practices.
- Dynamic data strategy agendas that overcome fragmentation and are representative of populations.
- Acknowledging deterioration of public trust in the use and commercialization of healthcare data through transparency and engagement
- Right governance in place for your critical data assets
- Addressing patients on social media
- Looking at issues around bluetooth hacking in medical devices
- How does data security deal with the technical framework of keeping data secure and available?
- How can we protect ourselves?
PATIENT EMPOWERMENT AND ACCESS
- How can we all work collaboratively to reexamine clinical trials and increase trust, awareness and engagement.
- The importance of embeding “patient centricity” into all aspects of a clinical trial
- Breaking down barriers to clinical trial recruitment and retention
- Barriers to accessing personalised medicine
- Strategies to ensure that patients have equitable access to medicines and health care
- Health technology assessment securing patient access to personalised medicine
- Innovative payer models
- Key factors influencing cost-effectiveness of personalised medicines
- Value-based approach to inform policy decisions about reimbursement and investment in research and development
- Societal perspective including opportunity costs, such as out-of-pocket patient costs, other indirect medical costs, also loss of income or productivity
- How can patient centricity play a vital role to personalised medicine?
- Understanding the paradigm for patient partnership
- Establishing trust at every patient touch-point to achieve sustained behavior change through informed decision-making.
- Building a more effective patient partnership models throughout the customer’s lifecycle
Newsletter Sign Up
No Spam – You will only receive relevant information on Personalized Medicine, and event updates
Tickets
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.
Advocates / Patient / Non Profit
£499
- 2 Day Congress + Full Access
- All Day Refreshments & Lunches
- Congress Documentations
- Networking Drinks Reception
Super Early Bird Discount
Available
£799
- 2 Day Congress + Full Access
- All Day Refreshments & Lunches
- Congress Documentations
- Networking Drinks Reception
Early Bird Discount Rate
Available
£999
- 2 Day Congress + Full Access
- All Day Refreshments & Lunches
- Congress Documentations
- Networking Drinks Reception
Standard Vendor Rate:
Full Price
£1299
- 2 Day Congress + Full Access
- All Day Refreshments & Lunches
- Congress Ducumentations
- Networking Drinks Reception
Standard Registration Rate
Full Price
£1299
- 2 Day Congress + Full Access
- All Day Refreshments & Lunches
- Congress Ducumentations
- Networking Drinks Reception
Testimonials
what people say
From a patient advocacy organization perspective, was a very informative meeting. Learned a lot from presentations and networking that will inform how we can add value to the advocacy-patient-drug developer dialogue.
Dr. Nadine Tutton
Scientific Director, Research, Association for Frontotemporal Degeneration
Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
SALVADOR BERRIOS
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
THOMAS MARTIN
Associate Vice President, VCGA - Quintiles
Previous events
Register to Attend now!
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.
Location
- London, UK
- info@paradigmglobalevents.com
- +44 (0) 207 193 3485